Abstract
This paper reports the first case of a patient with hepatocellular carcinoma with lymph node metastasis treated by sorafenib combined with gemcitabine plus oxaliplatin, with a partial response and normalization of α fetoprotein, which allowed curative surgery. The potential synergy between these three drugs needs to be confirmed, and is currently being investigated in a randomized phase II trial.
Keywords:
Gemcitabine; Hepatocellular carcinoma; Neoadjuvant therapy; Oxaliplatin; Sorafenib.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Benzenesulfonates / administration & dosage
-
Benzenesulfonates / therapeutic use*
-
Carcinoma, Hepatocellular / drug therapy*
-
Carcinoma, Hepatocellular / pathology
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Gemcitabine
-
Humans
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / pathology
-
Male
-
Middle Aged
-
Neoadjuvant Therapy*
-
Niacinamide / analogs & derivatives
-
Organoplatinum Compounds / administration & dosage
-
Organoplatinum Compounds / therapeutic use*
-
Oxaliplatin
-
Phenylurea Compounds
-
Pyridines / administration & dosage
-
Pyridines / therapeutic use*
-
Sorafenib
Substances
-
Benzenesulfonates
-
Organoplatinum Compounds
-
Phenylurea Compounds
-
Pyridines
-
Oxaliplatin
-
Deoxycytidine
-
Niacinamide
-
Sorafenib
-
Gemcitabine